secwatch.observer — SEC 8-K summary
======================================

Issuer:     Opus Genetics, Inc. (IRD)
CIK:        0001228627
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001140361-25-041544
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Opus Genetics Q3 net loss $17.5M; cash >$50M; LCA5 gene therapy gains FDA RMAT
------------------------------------------------------------------------------

- Q3 net loss of $17.5M ($0.25/sh) vs $7.5M ($0.29/sh) in prior year; revenue $3.1M from Viatris collaboration.
- Cash $30.8M at Sep 30; raised $23M post-quarter; total >$50M expected to fund into H2 2027.
- Positive LCA5 data: 3-month pediatric and 18-month adult gains in cone-mediated vision; FDA RMAT meeting supports accelerated approval pathway.
- BEST1 gene therapy trial recruiting; initial data Q1 2026. Phentolamine sNDA for presbyopia planned by year-end 2025.
- Non-dilutive funding: $1.6M from RDH12 Alliance and $2M from Retinal Degeneration Fund for MERTK program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1228627/000114036125041544/0001140361-25-041544-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1228627/000114036125041544/ef20058670_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-041544

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer